Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., Nov. 4, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Six quarters into Rezdiffra's launch, we continue to execu ...